POSB120 Economic Assessment of Ribociclib for the Treatment of Postmenopausal Patients with Advanced Breast Cancer HR-Positive, HER2-Negative.
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.393
https://www.valueinhealthjournal.com/article/S1098-3015(21)02188-4/fulltext
Section Title :
Section Order :
11173
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02188-4&doi=10.1016/j.jval.2021.11.393